Background/Aims: Azathioprine (AZA) has been widely used in the therapy of inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH). However, studies evaluating the adverse effects of AZA in these two diseases are lacking. The aim of this study was to compare the adverse effects of AZA in Korean IBD and AIH patients. Methods: Patients with IBD or AIH who were treated with AZA at Keimyung University Dongsan Medical Center (Daegu, Korea) between January 2002 and March 2011 were enrolled. Their medical records were reviewed retrospectively in terms of clinical characteristics and adverse effects of AZA. Results: A total of 139 IBD patients and 55 AIH patients were finally enrolled. Thirty IBD patients (21.6%) and eight AIH patients (14.5%) experienced adverse effects of AZA. In particular, the prevalence of leukopenia was significantly higher in the IBD group than in the AIH group (p=0.026). T474C mutation was observed in three of 10 patients who were assessed for thiopurine methyltransferase (TPMT) genotype. Conclusions: IBD patients are at increased risk for the adverse effects of AZA compared with AIH patients, of which leukopenia was the most commonly observed. Therefore, IBD patients receiving AZA therapy should be carefully monitored. (Korean J Gastroenterol 2014;64:348-355) 
INTRODUCTION
In Korea, the prevalence of inflammatory bowel disease (IBD) has shown a rapid increase owing to westernization of lifestyles and environmental changes during the last two decades. 1 Autoimmune hepatitis (AIH) is a rare chronic liver disease that should be treated immediately after diagnosis. 2 IBD and AIH are representative gastrointestinal diseases for which azathioprine (AZA) is used. AZA belongs to the family of thiopurines and is widely used as a maintenance steroid-sparing agent in both IBD and AIH. 3 In the past, due to safety concerns and delayed effects, clinicians were hesitant to use thiopurines in actual clinical practice even in compliant patients. However, their use has increased gradually Lee YJ, et along with recent studies showing the high efficacy and limited side effects of these agents. 4, 5 AZA-derived side effects can be categorized according to allergic and non-allergic reactions. 4, 6, 7 Allergic reactions that occur regardless of the administered dose include pancreatitis, fever, arthritis, skin rash, abdominal pain, diarrhea, and hepatitis. Symptoms appear quickly within 1-4 weeks after administration. Re-administration immediately results in manifestation of more severe side effects; therefore, the drugs cannot be used continuously in most cases. 5, 6, 8 On the other hand, non-allergic reactions include bone marrow suppression, such as leukopenia or thrombocytopenia, infection, and hepatitis. Non-allergic reactions appear relatively late, possibly after several months or years of administration. Although non-allergic reactions are mainly dose dependent, thiopurine methyltransferase (TPMT) genotype has been considered to play an important role in the occurrence of these adverse effects. 4, 9 One study compared the frequencies of the adverse effects occurring within a month after AZA treatment for
Crohn's disease (CD) and AIH 3 ; the results suggest that the frequencies of these adverse effects may vary according to underlying diseases. However, it remains unclear whether these results can be applied to Asians. 7, 10 In Korea, studies on the adverse effects of AZA in IBD patients have been conducted; however, few studies have examined the differences in adverse effects of AZA between IBD and AIH. Therefore, the aim of this study was to compare the adverse effects in patients with IBD and AIH who were treated with AZA in Korea.
In addition, we assessed TPMT gene polymorphism analysis in patients whose samples were available.
SUBJECTS AND MEDTHODS

Patients and study design
We retrospectively analyzed patients with IBD and AIH in whom AZA treatment was initiated at Keimyung University 
Statistical analysis
Qualitative data analyses were performed using the chisquare test or Fisher's exact test, whereas quantitative data analyses were performed using an independent-samples t-test. Data analyses were performed using IBM SPSS Statistics software version 19.0 (IBM Co., Armonk, NY, USA). A p-value of ＜0.05 was considered statistically significant.
RESULTS
Subjects' characteristics
A total of 224 patients (160 with IBD, 64 with AIH) received AZA during the studied period. Among 64 patients with AIH, nine were lost to follow up. Among 160 patients with IBD, eight patients had taken AZA before visiting our hospital, three had a history of AZA-induced side effects, and 10 were lost to follow-up. These patients were excluded from the study. Therefore, 139 patients with IBD (CD, 77; ulcerative colitis, 62) and 55 patients with AIH were eligible for this study ( Fig. 1 ). The characteristics of the studied population treated with AZA are shown in tively. In addition, nausea and vomiting, pancreatitis, and skin rash were noted in four subjects (2.9%), three subjects (2.2%), and one subject (0.7%), respectively. In the 55 patients with AIH, eight patients (14.5%) showed adverse ef- fects during AZA treatment. Leukopenia, anemia, and thrombocytopenia were identified in two (3.6%), two (3.6%), and three (5.5%) subjects, respectively. Acute pancreatitis induced by AZA occurred in three patients (2.2%) in the IBD group only, although it did not show statistical significance.
The occurrence of leukopenia after AZA administration was significantly higher in the IBD group than in the AIH group (15.1 vs. 3.6, p=0.026). Four patients with IBD and one patient with AIH were admitted to hospital due to leukopenia. Details of these patients are shown in Table 5 . Two patients with IBD and one patient with AIH had fever and chills. Pneumonia developed in two patients with IBD. All of these five patients were taking steroid at the time of leukopenia occurrence. Coadministration of mesalazine was observed in 3 of the 4 patients with IBD. After stopping AZA, leukopenia returned to normal in these five patients.
Development of leukopenia
TPMT gene polymorphism results
TPMT genotyping was performed in five patients with IBD and five patients with AIH. Among them, two patients with IBD and one patient with AIH showed TPMT*1S. Meanwhile, TPMT*1 was observed in three patients with IBD and four patients with AIH (Table 1 ). In TPMT*1S, the thymine (T) of the 474th nucleic acid of the 7th exon is replaced with a cytosine (C), which indicates the T474C mutation (Fig. 2) . Among patients with adverse effects, TPMT*1S was found in one patient with IBD and one patient with AIH without statistical difference.
이유진 등. IBD와 자가면역성 간염 환자에서 AZA의 부작용
The Korean Journal of Gastroenterology Values are presented as mean±SD, n (%), or median (range). IBD, inflammatory bowel disease; AIH, autoimmune hepatitis; AZA, azathioprine; WBC, white blood cell. Genotyping of the 7th exon shows that three patients have two different alleles of thymine (T) and cytosine (C). This heterozygous T474C silent mutation was confirmed for TPMT*1S. G, guanine; A, adenine.
DISCUSSION
According to Bajaj et al., 3 the incidence of allergic reactions was higher in the CD group (29%) than in the AIH group (5%). Concerning allergic reactions, except for nausea and vomiting, significant differences were found between the CD (19%) and AIH (12.5%) groups (p=0.001). However, neither the mechanisms of the differences in the allergic reactions between the two groups nor the non-allergic reactions, including leukopenia, were investigated. Therefore, this study analyzed the adverse effects, including bone marrow suppression, in patients with IBD and AIH. In addition, we analyzed the TPMT gene polymorphism, which is known to be the mechanism of conventional AZA adverse effects, albeit in a very small number of subjects.
Despite the reported frequency of adverse effects of AZA of 18-25% in patients with IBD and ＜10% in patients with AIH, serious adverse effects are uncommon. 8, 13, 14 In a report by Connell et al., 6 bone marrow suppression was observed in only 5% among 739 IBD patients treated with AZA. In most patients, leukocyte and platelet counts normalized after AZA was discontinued. Consistent with previous studies, in this study, there were no serious adverse effects or deaths, and all adverse effects resolved after the discontinuation or dose reduction of AZA.
In the current study, the common adverse effect asso- In addition, concomitant medications might also influence TPMT enzyme activity and can affect the safety and efficacy of thiopurines. Mesalazine, which is widely used in patients with IBD, has been reported to inhibit TPMT activity in vitro. 22, 23 This drug interaction might affect patients who inherit the characteristic of producing lower levels of the TPMT enzyme, and has important clinical significance in bone marrow suppression. However, we could not demonstrate any relationship between mesalazine medication and leukopenia occurrence, probably due to small sample size.
Several studies have suggested that patients on steroids have a decreased incidence of adverse effects. 8, 24 In this study, the development of total adverse effect was not significantly different between IBD and AIH, despite all patients with AIH on initial concomitant steroid therapy compared to 55.4% of IBD patients. Meanwhile, we observed that all patients admitted to hospital due to leukopenia were on concomitant steroid medication. Thus, we conclude that steroid may play a role as a predisposition to infection in patients with AZA-derived leukopenia.
Concerning the efficacy and toxicity of AZA, individual differences appear primarily because of the differences in TPMT activity, which is known to be associated with TPMT allele polymorphism. 25 The decrease of TPMT activity is known to be affected by the mutation allele type. Bone marrow suppression, the most common adverse effect of non-allergic reactions, showed a reverse correlation with TPMT activity. 13 Thus, it might be estimated by measuring the TPMT genotype and activity. On the basis of this theory, some studies have suggested that leukopenia can be prevented by measurement of the TPMT genotype or activity before AZA treatment. 9, 26, 27 Meanwhile, in other studies, bone marrow suppression and mutation of the TPMT genotype were not correlated in IBD or AIH. 10, 22, 27 Similarly, TPMT genotype was not associated with adverse effects in our study. However, because only small samples were investigated in our study, it is premature to conclude the relationship between the TPMT polymorphism and adverse effects. Conduct of more large scaled studies is warranted in the future.
In an analysis of the data of 621 patients with IBD who were treated with AZA by Fraser et al., 4 leukopenia was found in 29 patients (4.3%) and the duration of leukopenia onset after AZA administration varied. In the current study, the median interval of leukopenia onset after AZA use was 5.1 months in the IBD group and 0.93 month in the AIH group (Table 2) . This study has some limitations. First, the number of subjects differed between the two groups because of the retrospective design of this study. Second, the concomitant use of steroid or mesalazine differed between groups, thereby resulting in confounding variables. Third, the number of subjects who had results of TPMT genotype was too small, thus selection bias would exist. Fourth, 6-thioguanine nucleotide, the active factor of thiopurines, was not measured; thus, its relation with leukopenia in TPMT metabolism was not clearly
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In conclusion, the risk for the adverse effects of AZA was higher in patients with IBD compared to AIH, of which leukopenia was the most commonly observed. Therefore, patients with IBD receiving AZA should be closely monitored for possible adverse effects. Further large-scale studies are warranted in order to validate the effective use of AZA and the relation between AZA adverse effects and mutation of TPMT genotype according to disease.
